Positive News SentimentPositive NewsNASDAQ:KRRO Korro Bio (KRRO) Stock Price, News & Analysis → Beta testers blew this thing up (From Prosper Trading Academy) (Ad) Free KRRO Stock Alerts $34.72 -6.88 (-16.54%) (As of 06/17/2024 ET) Add Compare Share Share Today's Range$33.93▼$40.9950-Day Range$34.72▼$78.6952-Week Range$9.15▼$97.91Volume99,813 shsAverage Volume45,536 shsMarket Capitalization$321.85 millionP/E RatioN/ADividend YieldN/APrice Target$122.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Korro Bio alerts: Email Address Korro Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside252.8% Upside$122.50 Price TargetShort InterestHealthy2.52% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.77Based on 2 Articles This WeekInsider TradingAcquiring Shares$999,992 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($9.64) to ($10.73) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.54 out of 5 starsMedical Sector453rd out of 913 stocksPharmaceutical Preparations Industry207th out of 430 stocks 3.5 Analyst's Opinion Consensus RatingKorro Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageKorro Bio has only been the subject of 4 research reports in the past 90 days.Read more about Korro Bio's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted2.52% of the float of Korro Bio has been sold short.Short Interest Ratio / Days to CoverKorro Bio has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Korro Bio has recently decreased by 1.53%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldKorro Bio does not currently pay a dividend.Dividend GrowthKorro Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KRRO. Previous Next 3.2 News and Social Media Coverage News SentimentKorro Bio has a news sentiment score of 1.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.91 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Korro Bio this week, compared to 1 article on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Korro Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $999,992.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders16.80% of the stock of Korro Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 13.18% of the stock of Korro Bio is held by institutions.Read more about Korro Bio's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Korro Bio are expected to decrease in the coming year, from ($9.64) to ($10.73) per share.Price to Book Value per Share RatioKorro Bio has a P/B Ratio of 1.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Korro Bio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Prosper Trading Academywhy 99.94% won’t make you moneyI believe there's only 5-7 stocks that you should trade in 2024. But here's the catch…because there's always a catch in life. You NEED to use a specific system when you trade them.Click here to download my options trading cheat sheet (5-7 stocks inside here) About Korro Bio Stock (NASDAQ:KRRO)Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.Read More KRRO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KRRO Stock News HeadlinesMay 30, 2024 | globenewswire.comKorro to Participate in Upcoming June Investor and Scientific ConferencesMay 21, 2024 | markets.businessinsider.comBuy Rating Affirmed for Korro Bio Amid Promising KRRO-110 Preclinical Data and Superior Therapeutic ProfileMay 20, 2024 | globenewswire.comKorro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International ConferenceMay 18, 2024 | finance.yahoo.comKorro Bio, Inc. (KRRO)May 15, 2024 | markets.businessinsider.comKorro Bio Earns Buy Rating from Analyst Mitchell Kapoor on Groundbreaking RNA Editing Technology and Strong Preclinical ResultsMay 15, 2024 | finanznachrichten.deKorro Bio, Inc.: Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical OfficerMay 15, 2024 | investorplace.comKRRO Stock Earnings: Korro Bio Beats EPS for Q1 2024May 14, 2024 | globenewswire.comKorro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical OfficerApril 18, 2024 | globenewswire.comKorro Announces $70 Million Private PlacementApril 1, 2024 | globenewswire.comKorro to Participate in Upcoming Investor ConferencesMarch 26, 2024 | globenewswire.comKorro Reports Full Year 2023 Financial Results and Highlights Recent ProgressFebruary 27, 2024 | globenewswire.comKorro to Present at the TD Cowen 44th Annual Health Care ConferenceFebruary 18, 2024 | seekingalpha.comKorro Bio: An Interesting Platform With A Very Long HorizonSee More Headlines Receive KRRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Korro Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today6/17/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:KRRO Previous SymbolNASDAQ:KRRO CUSIPN/A CIK1703647 Webwww.frequencytx.com Phone781-315-4600FaxN/AEmployees101Year FoundedN/APrice Target and Rating Average Stock Price Target$122.50 High Stock Price Target$180.00 Low Stock Price Target$90.00 Potential Upside/Downside+252.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-81,170,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-80.45% Return on Assets-59.51% Debt Debt-to-Equity RatioN/A Current Ratio13.18 Quick Ratio13.18 Sales & Book Value Annual Sales$14.07 million Price / Sales22.88 Cash FlowN/A Price / Cash FlowN/A Book Value$21.19 per share Price / Book1.64Miscellaneous Outstanding Shares9,270,000Free Float7,715,000Market Cap$321.85 million OptionableNo Data Beta2.24 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Nessan Bermingham Ph.D. (Age 51)Co-Founder & Executive Chairman Comp: $202.14kMr. Ram Aiyar MBA (Age 46)Ph.D., CEO, President & Director Comp: $844.87kDr. Jean-Francois Formela M.D. (Age 67)MBA, Co-Founder & Director Comp: $8.21kMr. Vineet Agarwal M.B.A. (Age 42)Chief Financial Officer Comp: $811.77kDr. Steven L. Colletti Ph.D. (Age 58)Chief Scientific Officer Comp: $592.89kMr. Andrew Fraley Ph.D.Co-Founder & CTOMr. Josh Rosenthal Ph.D.Co-Founder & AdvisorMr. Todd Chappell (Age 51)Chief Operating Officer Ms. Shelby Walker J.D. (Age 49)Senior VP & General Counsel Mr. Ravi Ramadas Ph.D.Vice President of Business & Corporate DevelopmentMore ExecutivesKey CompetitorsArdelyxNASDAQ:ARDXSpyre TherapeuticsNASDAQ:SYRESchrödingerNASDAQ:SDGRAvadel PharmaceuticalsNASDAQ:AVDLBelite BioNASDAQ:BLTEView All CompetitorsInsiders & InstitutionsArtal Group S.A.Bought 621 shares on 5/17/2024Ownership: 4.522%Vanguard Group Inc.Sold 4,307 shares on 5/10/2024Ownership: 3.324%Venture Opportunity Fund AtlasBought 17,857 shares on 4/22/2024Total: $999,992.00 ($56.00/share)David L LucchinoSold 1,156 sharesTotal: $43,569.64 ($37.69/share)View All Insider TransactionsView All Institutional Transactions KRRO Stock Analysis - Frequently Asked Questions Should I buy or sell Korro Bio stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Korro Bio in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KRRO shares. View KRRO analyst ratings or view top-rated stocks. What is Korro Bio's stock price target for 2024? 4 Wall Street analysts have issued 12 month price targets for Korro Bio's stock. Their KRRO share price targets range from $90.00 to $180.00. On average, they predict the company's share price to reach $122.50 in the next year. This suggests a possible upside of 252.8% from the stock's current price. View analysts price targets for KRRO or view top-rated stocks among Wall Street analysts. How have KRRO shares performed in 2024? Korro Bio's stock was trading at $47.93 at the beginning of the year. Since then, KRRO stock has decreased by 27.6% and is now trading at $34.72. View the best growth stocks for 2024 here. When is Korro Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our KRRO earnings forecast. How were Korro Bio's earnings last quarter? Korro Bio, Inc. (NASDAQ:KRRO) announced its quarterly earnings results on Tuesday, May, 14th. The company reported ($2.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.36) by $0.08. Who are Korro Bio's major shareholders? Korro Bio's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Artal Group S.A. (4.52%) and Vanguard Group Inc. (3.32%). Insiders that own company stock include David L Lucchino and Venture Opportunity Fund Atlas. View institutional ownership trends. How do I buy shares of Korro Bio? Shares of KRRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KRRO) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and ra...Weiss Ratings | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredKiss of death from Joe BidenI did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but Biden does ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Korro Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Korro Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
